Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | NT5E | P21589 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Verazide SCHEMBL28784283 | 0.87 | MPO (0.82) | MPOGAANT5EKMT2AALDH1A1 | |
| Verazide SCHEMBL564065 | 0.87 | MPO (0.82) | MPOGAANT5EKMT2AALDH1A1 | |
| SCHEMBL12443618 | 0.81 | HTT (0.73) | MPOGAANT5EKMT2AALDH1A1 | |
| Ftivazide SCHEMBL436184 | 0.78 | GAA (1.00) | MPOGAANT5EKMT2AALDH1A1 | |
| SCHEMBL12443138 | 0.76 | KMT2A (0.82) | MPOGAANT5EKMT2AALDH1A1 | |
| SCHEMBL2542993 | 0.74 | GAA (0.80) | MPOGAANT5EKMT2AALDH1A1 | |
| SCHEMBL19283306 | 0.74 | GAA (0.67) | MPOGAANT5EKMT2AALDH1A1 | |
| SCHEMBL19283305 | 0.74 | GAA (0.67) | MPOGAANT5EKMT2AALDH1A1 | |
| SCHEMBL11983864 | 0.74 | SMN1; SMN2 (0.64) | GAAKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL28393887 | 0.74 | KMT2A (0.71) | KMT2AALDH1A1MEN1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 2012-01-12 | — | — | US | disclosed |
| US-8003692-B2 | Methods and compositions to inhibit edema factor and adenylyl cyclase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2166841-A2 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | Mission Pharmacal Company (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | MISSION PHARMACAL CO. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2009038842-A2 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | MISSION PHARMACAL CO. (US) | 2009-03-26 | — | — | WO | disclosed |
| EP-1356071-B1 | GENETICALLY ENGINEERED HERPES VIRUS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | UNIV CHICAGO (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20070032409-A1 | Bradykinin receptor antagonists and uses thereof | VANDERBILT UNIVERSITY (US) | 2007-02-08 | — | — | US | disclosed |
| WO-2006135660-A2 | THERAPIES INVOLVING LYMPHOTOXIN BETA RECEPTOR | UNIVERSITY OF CHICAGO (US) | 2006-12-21 | — | — | WO | disclosed |
| US-6846670-B2 | Genetically engineered herpes virus for the treatment of cardiovascular disease | THE UNIVERSITY OF CHICAGO (US) | 2005-01-25 | — | — | US | disclosed |
| EP-1356071-A2 | GENETICALLY ENGINEERED HERPES VIRUS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | The University of Chicago (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20020155432-A1 | Genetically engineered herpes virus for the treatment of cardiovascular disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-10-24 | — | — | US | disclosed |
| WO-2002045431-A2 | GENETICALLY ENGINEERED HERPES VIRUS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | THE UNIVERSITY OF CHICAGO (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | VIP, PDE3B, ADCY5 | MPO 424/4885GAA 2033/4885NT5E 126/4885 |
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | VIP, PDE3B, ADCY5 | MPO 424/4885GAA 2033/4885NT5E 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.